For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Vyndamax and Tafamidis meglumine represents a genuine advancement . These novel therapies stabilize the transthyretin protein, preventing its damaging build-up and reducing the im